Straits Times Index
3,405.81 +37.91 (+1.13%) Nikkei
40,631.70 +557.01 (+1.39%) Hang Seng
17,923.25 +154.11 (+0.87%) FTSE 100
8,121.20 -45.56 (-0.56%) Bitcoin USD
60,911.25 -2,051.20 (-3.26%) CMC Crypto 200
1,310.78 -33.72 (-2.51%)
CDMO Dec 2024 5.000 call
- GlobeNewswire
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Three-Year Expansion Program Completed -- -- FY 2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedic
- GlobeNewswire
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
- Simply Wall St.
Those who invested in Avid Bioservices (NASDAQ:CDMO) five years ago are up 104%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
